Global NGS-based RNA-seq Market to Grow by £3.75 Billion During 2023-2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 22, 2022--
The “Global NGS-based RNA-seq Market 2023-2027” report has been added to ResearchAndMarkets.com’s offering.
The NGS-based RNA-seq market is poised to grow by $3,753.73 mn during 2023-2027, accelerating at a CAGR of 15.34% during the forecast period. The report on the NGS-based RNA-seq market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increased adoption of next-generation sequencing methods, technological advancement in sequencing platforms, and the availability of wide range of next generation sequencing products.
The NGS-based RNA-seq market is segmented as below:
- Academic and research centers
- Clinical research
- Pharma companies
- Sequencing by synthesis
- Ion semiconductor sequencing
- Single-molecule real-time sequencing
By Geographical Landscape
- North America
- Rest of World (ROW)
This study identifies the advances in next-generation sequencing techniques as one of the prime reasons driving the NGS-based RNA-seq market growth during the next few years. Also, reduced costs of gene sequencing and developments in the field of bioinformatics and cloud-based software programs will lead to sizable demand in the market.
The report on the NGS-based RNA-seq market covers the following areas:
- NGS-based RNA-seq market sizing
- NGS-based RNA-seq market forecast
- NGS-based RNA-seq market industry analysis
Key Topics Covered:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Technology
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
- Agilent Technologies Inc.
- BGI Genomics Co. Ltd.
- Brooks Automation Inc.
- DNASTAR Inc.
- Eurofins Scientific SE
- F. Hoffmann La Roche Ltd.
- Hamilton Bonaduz AG
- Illumina Inc.
- Precigen Inc.
- Pacific Biosciences of California Inc.
- PerkinElmer Inc.
- PierianDx Inc.
- Psomagen Inc.
- QIAGEN NV
- Takara Bio Inc.
- Tecan Trading AG
- Thermo Fisher Scientific Inc.
- Zymo Research Corp.
For more information about this report visit https://www.researchandmarkets.com/r/2zjcj
View source version on businesswire.com:https://www.businesswire.com/news/home/20221222005187/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 12/22/2022 04:16 AM/DISC: 12/22/2022 04:17 AM